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CAPSULE 
Recipients using oocytes from donors aged ≥35 years had a significantly lower cumulative 
live birth rate (CLBR) when compared to recipients using ooctyes from donors aged <35 
years. 
STRUCTURED ABSTRACT 
Objective: To study the impact of the donor’s and recipient’s age on the cumulative live 
birth rate (CLBR) in oocyte donation cycles?  
Design:    A population-based retrospective cohort study  
Setting: Data obtained from the Victorian Assisted Reproductive Treatment Authority 
(VARTA) in Victoria, Australia. 
Patient(s): All women using donated oocytes (n = 1,490) in Victoria, Australia between 2009 
and 2015 were included. 
Intervention(s): None 
Main Outcome Measure(s): The association between the donor’s and recipient’s age and 
CLBR was modelled by multivariate Cox proportional hazard regression with the following 
covariates adjusted for: male partner’s age, recipient parity and cause of infertility. Donor 
age was grouped as <30, 30-34, 35–37, 38-40 and ≥41 years, and recipient age as <35, 35–
37, 38–40, 41-42, 43-44 and ≥45 years. 
Results: The mean age of the oocyte donors was 33.7 years (range 21 to 45 years) with 49% 
aged 35 years and over. The mean age of the oocyte recipients was 41.4 years (range 19 to 
53 years) with 25.4% aged ≥45 years. There was a significant relationship between the 
 
 
donor’s age and the CLBR. The CLBR for recipients with donors aged <30 years and 30-34 
years was 44.7% and 43.3% respectively. This decreased to 33.6% in donors aged 35-37 
years, 22.6% in donors aged 38–40 years and 5.1% in donors aged ≥41 years. Compared 
with recipients with donors aged <30 years, recipients with donors aged 38-40 years had 
40% less chance of achieving a live birth (AHR 0.60, 95% CI 0.43–0.86) and recipients with 
donors aged ≥41 years had 86% less chance of achieving a live birth (AHR 0.14, 0.04–0.44). 
The multivariate analysis showed no significant effect of the recipient’s age on CLBR.  
Conclusion: We demonstrate that the age of the oocyte donor is critical to the CLBR and is 
independent of the recipient woman’s age. Recipients using oocytes from donors aged ≥35 
years had a significantly lower CLBR when compared to recipients using ooctyes from 
donors aged <35 years. 




Since the world’s first live birth using donated oocytes was reported in 1984 (1) the number 
of oocyte donation cycles has grown considerably. Currently, in Australia, oocyte donation 
represents 5.6% of all assisted reproductive treatment (ART) cycles (2), while in Europe and 
the United States it accounts for approximately 4.5% (3) and 12% (4) respectively. Oocyte 
donation is an important component of ART particularly for women with age-related 
infertility, poor ovarian reserve, and for women who carry genetic abnormalities (5). 
In Australia, only altruistic gamete donation is permitted. Altruistic donors are usually 
parous and cohabiting or married, unlike the majority of compensated donors who are 
nulliparous and single (6). This may partly explain why altruistic donors are on average are 
older than compensated donors. The average age of women donating oocytes in Australia in 
2016 was 32.6 years, with 40.8% of cycles involving donors aged 35 or older (2). Apart from 
compensation for expenses incurred as a result of donating oocytes, a donor cannot receive 
any payment or other inducement as per the Prohibition of Cloning Act 2002 (7). 
Furthermore, the Australian National Health and Medical Research Council (NHMRC) Ethical 
Guidelines (8) and the Fertility Society of Australia Reproductive Technology Accreditation 
Committee (RTAC) Code of Practice (9) stipulate that children born as a result of oocyte 
donation have the right to access information about the donor when they reach the age of 
18. 
Cycle-based evidence shows that live birth rates with oocyte donation are dependent on the 
age of the donor, where recipients with younger donors have a higher live birth rate than 
those with older donors (10). There is also evidence showing a relationship between ART 
outcomes and uterine receptivity in older oocyte recipient women. In 2002, Toner et al. (11) 
 
 
performed a retrospective analysis of oocyte donation data gathered by the Society for 
Assisted Reproductive Technology (SART) registry. They found ART outcomes declined in 
recipients >45 years and declined further in recipients >50 years. Similarly, Yeh and 
colleagues found that recipients on the SART database between 2008 and 2010 had stable 
rates of pregnancy outcomes <45 years but this declined in recipients >45 years (12). They 
conclude that there is relationship between ART outcomes, oocyte donor age and uterine 
receptivity in older women.  
However, there is no international agreement on “how old is too old”. It is known that 
women over 35 years have a higher aneuploidy rate and fewer oocytes retrieved following 
hormonal stimulation than younger women (13). Therefore, ideally oocyte donors are 
women in their 20’s and early 30s, who are in good health and free from heritable 
conditions (14, 15). In Australia, it is recommended that clinics do not use oocytes provided 
by ‘older’ donors, though no upper age limit is specified (8). However, because of the 
shortage of donors, most recipients use a willing friend or relative as their donor and ART 
clinics accept them irrespective of their age (16). Hence, women older than 35 years are 
accepted when they donate to a specific recipient, who has been counselled about the 
implications of the donor’s age. Similarly in countries in Europe, where commercial donation 
is prohibited, the upper age limits of oocyte donors may be interpreted flexibly in cases of 
direct donation because there is a great scarcity of donors and thus no alternative (13).   
When a woman or couple enquire about oocyte donation they want to know if the 
treatment will result in a healthy baby (17). Artificial reproductive technology success rates 
following oocyte donation are usually presented as outcome per cycle or embryo transfer 
according to donor’s age (18). However, Malizia and colleagues (17) maintain that this 
 
 
statistic has limited value because it does not account for the additional chance offered by 
frozen embryos resulting from a stimulated cycle. It is argued that the CLBR has more 
significance for recipients and clinicians because it provides an overall estimate of the 
chance of having a baby following one stimulated cycle (19). The purpose of this population-
based cohort study is to provide population statistics on the effect of the oocyte donor’s 
and recipient’s age on the CLBR in oocyte donation cycles. 
Materials and Methods 
Data 
In the state of Victoria in Australia, only registered ART providers can offer ART. Data used in 
this study are collected from all registered ART providers in Victoria by the Victorian 
Assisted Reproductive Treatment Authority (VARTA) and the University of Technology 
Sydney (UTS). VARTA is a statutory authority funded by the Victorian Department of Health 
and Human Services in Victoria.  Among its obligations, VARTA is responsible for monitoring 
and reporting on all ART procedures carried out in registered clinics.  
All women using donated oocytes (n = 1,490) in Victoria, Australia between 2009 and 2015 
were included. This included women since 2013, who obtained donor oocytes from The 
World Egg Bank in the United States. 
Data collected for oocyte recipient cycles include age, parity, cause of infertility, number of 
oocytes donated and received, fertilization procedure (IVF or ICSI), stage of embryo at 
transfer, and number of fresh and thawed embryos created and transferred. Data on the 
outcomes of resulting pregnancies and births, including birth status, gestational age, birth 
weight and congenital anomalies, are also collected.   
 
 
Data on fresh and frozen embryo transfers following oocyte donation undertaken from 1 
July 2009 to 30 June 2016, or until a live birth was achieved, and resulting pregnancy and 
birth outcomes were extracted from the VARTA database and are included in this study. 
Study factors 
The donors’ ages were calculated in completed years at the time of oocyte donation and 
classified into five groups: <30, 30-34, 35–37, 38-40, and ≥41 years. The recipients’ ages 
were calculated at the time of first transfer and categorized into six groups: <35, 35–37, 38–
40, 41-42, 43-44, and ≥45 years. The cause of infertility was classified as male factor 
infertility, female factor infertility, combined male-female factor infertility, unexplained 
infertility and not stated. 
Previous pregnancy of ≥20 weeks gestation was grouped as yes, no and not stated. 
Fertilisation procedure was either IVF or ICSI. Stage of embryo development was grouped 
into cleavage or blastocyst stages. The number of embryos transferred in each cycle was 
grouped as one or two embryos. 
Main outcome measure 
The primary outcome was the cumulative live birth rate (CLBR), defined as at least one live 
birth following one oocyte donation, including fresh and any associated frozen embryo 
transfers. A live birth was defined as a baby showing signs of life with gestational age ≥ 20 
weeks or birthweight ≥ 400 grams. The observed CLBR was reported using the conservative 
assumption that women who did not return for treatment did not have a pregnancy 




Chi-squared test was used for categorical variables. Cox regression was used to model the 
association between the donor’s and recipient’s age and CLBR. The adjusted hazard ratio 
(AHR) and 95% confidence intervals (CI) were calculated. Adjustment was made for the male 
partner’s age, recipient parity (nulliparous/parous) and, cause of infertility (male 
only/female only/combined male-female/unexplained). A p-value <0.05 was considered 
statistically significant. All statistical analysis was performed using SPSS 24.0 software 
(Armonk, NY, USA: IBM Corp.). 
Ethics 
Ethics approval for this study was granted by the Human Research Ethics Committee of the 
University of Technology Sydney, Australia (UTS HREC REF NO. ETH16-0800). Access to the 
VARTA data was granted by VARTA. 
Results 
In all 1490 oocyte recipients had 2919 fresh and frozen embryo transfer cycles. 
Characteristics of donors and recipients are shown in Table 1. The mean age of the oocyte 
donors was 33.7 years (range 21 to 45 years) with 50.4% aged <35 years. The mean age of 
the oocyte recipients was 41.4 years (range 19 to 53 years) with one quarter (25.4%) aged 
≥45 years. Overall one in five recipients (21.9%) had a history of a previous pregnancy ≥20 
weeks. The mean number of oocytes received was 11.93 (range 11.28 to 12.51) and was 




Table I: Selected demographics of participants in oocyte donor/recipient cycles 
 
  
Oocyte recipients’ age group (years) 















Donors’ age group 
(years)        
 
Mean (yr) 32.8 33.9 34.9 33.9 33.5 33.2 33.7 
 
< 30 44(23.1) 31(18.2) 26(10.6) 40(17.1) 59(21.9) 93(24.6) 293(19.7) 
 
30-34 80(41.9) 53(31.0) 75(30.5) 69(29.5) 73(27.0) 107(28.3) 457(30.7) 
 
35-37 42(22.0) 57(33.3) 81(32.9) 72(30.8) 68(25.2) 94(24.9) 414(27.8) 
 
38-40 23(12.0) 25(14.6) 46(18.7) 39(16.6) 51(18.9) 50(13.2) 234(15.7) 
 
≥41 2(1.0) 4(2.3) 16(6.5) 12(5.1) 17(6.3) 27(7.1) 78(5.2) 
 Unknown 0(0) 1(0.6) 2(0.8) 2(0.9) 2(0.7) 7(1.9) 14(0.9) 
 
All 191(100) 171(100) 246(100) 234(100) 270(100) 378(100) 1490(100) 
Infertility diagnosis 




Male factor 22(11.5) 24(14.0) 29(11.8) 26(11.1) 37(13.7) 45(11.9 183(12.3) 
 




33(17.3) 34(19.9) 38(15.4) 44(18.8) 37(13.7) 61(16.1) 247(16.6) 
 
Unexplained 18(9.4) 16(9.4) 27(11.0) 23(9.8) 27(10.0) 45(11.9) 156(10.5) 
 
Not stated 64(33.5) 57(33.3) 93(37.8) 95(40.6) 106(39.3) 126(33.3) 541(36.3) 
Previous pregnancy of ≥20 weeks 
gestation       
 
 27(14.1) 35(20.5) 55(22.4) 54(23.1) 50(18.5) 106(28.0) 327(21.9) 
 
The proportion of blastocyst transfer observed in cycles of recipients aged <35 years (50.2%) 
was not significant when compared to older recipients (45.2%). Double embryo transfer 
accounted for 23.4% of all embryo transfers and was most common in recipients in the 35-
37 years age group (29.9%) (Table 2). There were 44 twin births, of which 38 (86.4%) 
occurred following double embryo transfers. We observed that the age of the oocyte donor 




Table II: Treatment factors of embryo transfer cycles 

















      
  ICSIa 227(83.2) 212(83.5) 342(89.8) 328(90.4) 393(88.1) 590(87.3) 2092(87.4) 
Stage of embryo 
development 
     
  Blastocyst 137(50.2) 117(46.1) 174(45.7) 159(43.8) 194(43.5) 316(46.7) 1097(45.8) 
Number of embryos 
transferred 
     
  1 207(75.8) 178(70.1) 289(75.9) 278(76.6) 333(74.7) 574(80.9) 1832(76.6) 
  2 66(24.2) 76(29.9) 92(24.1) 85(23.4) 113(25.3) 129(19.1) 561(23.4) 
Total 273 254 381 363 446 676 2393 
aIntracytoplasmic Sperm Injection 
The CLBR ranged from 31.7% among recipients aged 38-40 years to 41.4% among recipients 
aged <35 years. The multivariate analysis showed no significant differences in the success by 
recipient’s age (Table 3). The CLBR by cycle is provided in the Supplementary Tables (1-7). 
Table III: Cumulative live birth rates in oocyte recipient cycles by age of recipients and donors 
 Cumulative Live birth  
 
 Rate (%) HR hazard ratio AHR adjusted hazard ratio 
Recipient's age (years)a    
<35 41.4% Ref Ref 
35-37 38.0% 0.93(0.67,1.29) 1.07(0.73,1.56) 
38-40 31.7% 0.71(0.52,0.97) 0.90(0.62,1.30) 
41-42 32.9% 0.77(0.56,1.06) 0.88(0.59,1.30) 
43-44 37.8% 0.88(0.65,1.17) 1.06(0.73,1.54) 
≥45 33.3% 0.74(0.56,0.98) 0.92(0.63,1.33) 
Donor's age (years)    
<30 44.7% Ref  
30-34 43.3% 1.01(0.81,1.26) 1.07(0.84,1.36) 
35-37 33.6% 0.75(0.59,0.96) 0.80(0.61,1.03) 
38-40 22.6% 0.55(0.40,0.75) 0.60(0.43,0.86) 
≥41 5.1% 0.13(0.05,0.36) 0.14(0.04,0.44) 
aAdjustment was made for male age, parity and cause of infertility 
There was a significant association between the donor’s age and CLBR. The CLBR for 
recipients with donors aged <30 years and 30-34 years was 44.7% and 43.3% respectively. 
 
 
This decreased to 33.6% in donors aged 35-37 years, 22.6% in donors aged 38-40 years and 
5.1% in donors aged ≥41 years. Compared with recipients with donors aged <30 years, 
recipients with donors aged 38-40 years had 40% less chance of achieving a live birth (AHR 
0.60, 95% CI 0.43–0.86) and recipients with donors aged ≥41 years had 86% less chance of 
achieving a live birth (AHR 0.14, 0.04–0.44) (Table 3). 
When oocyte recipient and donor ages were combined the highest cumulative live birth rate 
was in recipients aged 35-39 years with donors aged <30 years (51.1%). The lowest 
cumulative live birth rate was in recipients aged ≥45 years and donors aged ≥40 years (5.3%) 
(Table 4).  
Table IV Cumulative live birth rate by recipient and donor ages 
Donor age Recipient age 
 <35 35-39 40-44 ≥45 All 
<30 50.0% 51.1% 40.4% 44.1% 44.7% 
30-34 46.3% 42.4% 47.2% 35.5% 43.3% 
35-39 28.8% 30.7% 30.3% 33.8% 31.0% 
≥40 37.5% 10.0% 10.4% 5.3% 10.5% 
All 41.4% 35.3% 34.8% 33.3% 35.4% 
 
Discussion 
This population-based cohort study, on outcomes of oocyte donation, found that recipients 
with donors aged 35 years or older had a significantly lower CLBR, regardless of the recipient’s 
age. To the best of our knowledge, there are no other studies that have evaluated the CLBR 
in women who have received donated oocytes. 
The mean age of the oocyte donors in this study was 33.7 years. This is significantly older 
than the average age of donors in European (13) and United States (20) studies of 27.4 years 
 
 
and 28 years respectively. In Australia, only altruistic gamete and embryo donation is 
permissible but there are no regulations that set an age limit for oocyte donation (8, 9). 
Artificial reproductive technology clinics accept older donors because the demand for 
donated oocytes exceeds supply (16). This may in part explain the finding that almost half 
(49%) of the oocyte donors in this study were 35 years of age or older. This is similar in the 
United Kingdom where only altruistic oocyte donation is permitted and the upper age limit 
of women donating oocytes may be interpreted flexibly because of the scarcity of donors 
(13). 
The mean age of the oocyte recipients in this study was similar to the ages of recipients 
reported in studies in the United States (20) and the United Kingdom (13). A range of 
circumstances can lead women of advanced reproductive age to request oocyte donation to 
overcome age-related infertility such as having experienced repeated fertility treatment 
failure, being single or finding a partner later in life, being in a second long-term 
relationship, or having experienced the loss of a child (5, 21). Younger women may also 
need oocyte donation if their fertility has been compromised by gonadotoxic agents (for 
example due to chemotherapy) or if they have a genetic inheritable disorder or primary 
ovarian insufficiency (12). 
In the current study we were not able to confirm if the women donating oocytes were 
known to the recipients because this information is not collected by VARTA. As Australian 
women must rely on altruistic egg donors, the donors are often family members, close 
friends, or colleagues who may be closer in age to the recipients than compensated donors 
might have been (22). Additional to local donation, patients in Victoria have legally been 
able to recruit oocyte donors from The World Egg Bank since 2013.  
 
 
Intrafamily donation is not uncommon and generally regarded positively. One of the first 
studies to report on this was by Sauer and colleagues (23) who surveyed a small group of 
couples undergoing IVF with donated oocytes. They concluded that the acceptability of 
using a sister for gamete donation is high among couples desiring oocyte donation. More 
recent studies also demonstrate that women prefer sisters as their donors because they 
value the genetic connection with the child (24, 25). A recent survey of more than 2000 
United States residents by Bortoletto et al. (26), reported that oocyte donation from a 
family member was viewed favourably by 86% of the respondents as it made access to 
oocytes a reality for infertile individuals or couples. 
Oocyte Ageing  
Previous studies on oocyte donation have indicated that oocyte ageing makes a much larger 
contribution than uterine deterioration to the age-related decline of fecundity and that 
oocytes from younger donors markedly improves the chances of pregnancy in women of 
advanced reproductive age (10, 27, 28). This is supported by the findings of the current 
study: when the oocyte recipients’ and donors’ ages were combined, (i) the highest CLBR 
was in recipients aged 35-39 years with donors aged <30 years (51.1%), and (ii) the lowest 
CLBR was in recipients aged ≥45 years with donors aged ≥40 years (5.3%). However, if a 
recipient woman aged ≥40 years received oocytes from a donor ≤34 years, they had a 
similar chance of having a live birth as a younger recipient with a young donor. In order to 
eliminate the possibility of a confounder, we adjusted for both the age of the donor and the 
age of the recipient and there was no similarity found between their ages.  
When looking at the donor’s age alone, the CLBR was 5.1% for recipients with donors aged 
over 41 years. The latest Australian and New Zealand Assisted Reproductive Data report 
 
 
shows that the cycle specific live birth rate for women aged 40-44 years using their own 
eggs was 4.9% after the fourth cycle and 3.9% after eighth cycle (2). This indicates that the 
age of oocyte is a critical factor and lends support to the requirement for an upper age limit 
for oocyte donors. Recipients with donors aged 40 or younger can succeed one live birth per 
every five oocyte donation/recipient arrangements.  
The need to move to reporting CLBR based on individual patient data, rather than live birth 
rates per cycle, has been highlighted (17, 19). Currently, the success rate of ART is generally 
reported as the number of clinical pregnancies or live births per single fresh or frozen/thaw 
embryo transfer. McLernon and colleagues (18) agree that the CLBR is more meaningful to 
women/couples and clinicians than cycle-based success rates making the results of this 
study relevant for clinicians and patients. 
Study Limitations 
A limitation of this population-based study is the lack of information available on clinic-
specific protocols and processes for ART and the potential impact of these on clinical 
outcomes. The management of both female gametes (such as oocyte degeneration and 
choice of ICSI timing) and male gametes (such as DNA fragmentation) may affect the efficacy 
of ART treatments (29). Further studies are required to evaluate the influence of these kinds 
of technical aspects on clinical outcomes. Demographic confounders including obesity and 
cigarette smoking, medical complications and other residual confounders, which may have 
affected the findings of this study, are not recorded in the VARTA dataset. In addition, 
information about the cause of infertility was not recorded in around one third of cases. 




In conclusion, this study suggests that the age of the oocyte donor is critical to the CLBR and 
is independent of the recipient woman’s age. The cumulative success rates derived from the 
present data can be used in the counselling of couples at the start of treatment or when 
making decisions about treatment continuation, if one or more cycles have been 
unsuccessful. The findings of this study lend support to the requirement for an upper age 
limit for oocyte donors. From a public health perspective, there is justification for 
advocating oocyte donors, ideally ≤35 years but under 41 years, with the aim to reach above 
20% CLBR. 
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